Catalog No: OAAB16691
Price: $389.00
Availability: Domestic: within 1-2 week delivery | International: within 1-2 week delivery
Contact Us:
Shipping Info:
  • $55: Antibody & Protein in US
  • $55 + $25/Kit in US
  • Contact us for international orders.
Datasheets/ManualsPrintable datasheet for OAAB16691
Product Info
Predicted Species ReactivityHuman
Product FormatLiquid. PBS with 0.09% (W/V) sodium azide.
ApplicationWB, FC, IF, IHC-P
Additional InformationFunction: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'- linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene

Cellular Location: Cytoplasm, cytosol. Nucleus. Endoplasmic reticulum. Mitochondrion. Note=Mainly localizes in the cytosol Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential; recruitment to mitochondria is PINK1-dependent
Tissue Location: Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum (at protein level)
Reconstitution and StorageMaintain refrigerated at 2-8C for up to 2 weeks. For long term storage store at -20C in small aliquots to prevent freeze-thaw cycles.
ImmunogenThis Parkin antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 111-140 amino acids from the N-terminal region of human Parkin.
PurificationThis antibody is purified through a protein A column, followed by peptide affinity purification.
ConcentrationApproximately 0.5mg/ml. Actual concentration varies with each lot.
Sample Type Confirmation

PARK2 is strongly supported by BioGPS gene expression data to be expressed in NCI-H460

Intended UseParkin Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.
Application InfoWB: 1:250~1:1000
FC: 1:10~50
IF: 1:10~50
IHC-P: 1:10~50
Gene SymbolPARK2
Alias SymbolsPDJ, AR-JP, LPRS2, PARK2
NCBI Gene Id5071
Protein NameE3 ubiquitin-protein ligase parkin
Description of TargetParkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson disease identified to date. The function of Park2 is not well-known; however, it may play a role in the ubiquitin-mediated proteolytic pathway. Mutations in this gene are known to cause autosomal recessive juvenile parkinsonism. Alternative splicing of this gene produces three known products of undetermined function.
Uniprot IDO60260
Protein Accession #NP_004553.2
Molecular Weight51641 Da
  1. What is the species homology for "Parkin Antibody - N-terminal region (OAAB16691)"?

    The tested species reactivity for this item is "". This antibody is predicted to have homology to "Human".

  2. How long will it take to receive "Parkin Antibody - N-terminal region (OAAB16691)"?

    This item is available "Domestic: within 1-2 week delivery | International: within 1-2 week delivery".

  3. What buffer format is "Parkin Antibody - N-terminal region (OAAB16691)" provided in?

    This item is provided in "Liquid. PBS with 0.09% (W/V) sodium azide.".
    Additional format options may be available. For more information please contact info@avivasysbio.com.

  4. What are other names for "Parkin Antibody - N-terminal region (OAAB16691)"?

    This target may also be called "PDJ, AR-JP, LPRS2, PARK2" in publications.

  5. What is the shipping cost for "Parkin Antibody - N-terminal region (OAAB16691)"?

    The shipping cost for this item is $40 within the US. Please contact us for specific shipping prices for international orders.

  6. What is the guarantee for "Parkin Antibody - N-terminal region (OAAB16691)"?

    All Aviva products have been through rigorous validations and carry 100% satisfaction guarantee.

  7. Can I get bulk pricing for "Parkin Antibody - N-terminal region (OAAB16691)"?

    You can get bulk pricing for this item by going here.

  8. What is the molecular weight of the protein?

    The molecular weight reported by Uniprot for this item is "51641 Da".
    Please note observed molecular weights in western blot applications may differ depending on a variety of protein characteristics.

  9. What protocols are available for "Parkin Antibody - N-terminal region (OAAB16691)"?

    We may have detailed protocol data avaialble for this item. To learn more, please view the "Protocols & Data" tab on the product page.

  10. What are positive controls for "PARK2"?

    We have listed RNA Seq and gene expression data in the "Target Info" tab. You may be able to find adequate positive controls there.

  11. What are negative controls for "PARK2"?

    We have listed RNA Seq and gene expression data in the "Target Info" tab. You may be able to find adequate positive controls there.

  12. What other proteins interact with "PARK2"?

    This protein has been reported to interact with "Protein Interactions". Please view the "Related Categories" tab on the product page for more information.

  13. What biological processes are associated with "PARK2"?

    This protein has been associated with "Biological Processes". Please view the "Related Categories" tab on the product page for more information.

  14. What cellular components are associated with "PARK2"?

    This protein has been associated with "Cellular Components". Please view the "Related Categories" tab on the product page for more information.

  15. What protein functions are associated with "PARK2"?

    This protein has been associated with "Protein Functions". Please view the "Related Categories" tab on the product page for more information.

Write Your Own Review
You're reviewing:Parkin Antibody - N-terminal region (OAAB16691)
Your Rating
We found other products you might like!